Curated CRC research, accessible, accurate, actionable

The CRC Digest

Saturday, October 17, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  Serrated polyp detection rate may predict post-colonoscopy colorectal cancer beyond adenoma detection alone

  Among endoscopists with high adenoma detection rates, those with higher proximal serrated polyp detection rates (≥10%) had lower 5-year post-colonoscopy colorectal cancer incidence (0.06%) compared to those with lower rates (0.13%), suggesting serrated polyp detection provides complementary information for quality assessment. (Endoscopy)

• ▪ SCREENING

  Colorectal neoplasia detected at young age in Li-Fraumeni syndrome surveillance

  In seven women with Li-Fraumeni syndrome, colorectal neoplasia was detected in five patients at a median age of 32.5 years, including one colorectal cancer at age 32 and three advanced adenomas; four patients developed lesions within 2-3 years after a negative baseline colonoscopy. (Clinical Journal of Gastroenterology)

• ◇ RESEARCH

  Whole genome sequencing-based ctDNA assay detects molecular residual disease across solid tumors

  In a pan-cancer cohort including colorectal cancer patients, those with ctDNA-positive molecular residual disease at 3 months post-surgery had significantly shorter recurrence-free survival (HR 23.7) compared to ctDNA-negative patients, and 62% of detections occurred at ultra-sensitive levels below 100 parts per million. (The Oncologist)

This week's research highlights advances in screening quality metrics, liquid biopsy for recurrence monitoring, and regulatory confirmations for biomarker-selected immunotherapy.